<DOC>
	<DOCNO>NCT01214590</DOCNO>
	<brief_summary>The purpose study assess safety preliminary efficacy treatment VascuActive device peripheral diabetic neuropathy , correlate effect physiologic change . Patients undergo 4-week period home treatment VascuActive device , monitor period two-month follow-up period efficacy device reduce neuropathic pain , sensation impairment sign symptom .</brief_summary>
	<brief_title>Preliminary Assessment Efficacy VascuActive™ Device Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Diabetes Mellitus ( type 1 2 ) Age 18 year old No change within last 3 month diabetes medication , pain management medication , symptom associate diabetes Painful diabetic neuropathy &gt; 3 month , 5 year Pain level ≥ 4 11 point Numerical Pain Rating Scale foot ( average two measurement , least 1 week apart , 2 week prior first treatment ) Loss protective sensation 5.07 SemmesWeinstein Monofilament ( SWM , 10gr . ) monofilament test ( foot , least 3 10 point foot ) Known suspect radiculopathy ( base patient 's record anamnesis ) Any painful condition difficult distinguish painful diabetic peripheral neuropathy Women age fertility , pregnant , plan pregnancy , use contraceptive Severe cardiac disease surgery within last 3 month , e.g. , Acute Myocardial Infarction , Congestive Heart Failure grade 3 high Any major infectious , malignant severe systemic disease , include limited Acquired Immune Deficiency Syndrome ( AIDS ) , hepatitis , CreutzfeldtJakob disease Patient incompetent comply study requirement ( investigator 's opinion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>